Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3XT5V)

Drug Name

APD371 Drug Info

Synonyms

Olorinab; UNII-581F7DFA9B; 581F7DFA9B; Olorinab [USAN]; SCHEMBL11995430; 1268881-20-4; (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide; 1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-; (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic aci

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 2	[1]

Cross-matching ID

PubChem CID: 60164925
CAS Number: CAS 1268881-20-4
TTD Drug ID: DM3XT5V

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[3]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[4]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[5]
LY-2828360	DMO8IEZ	Pain	MG30-MG3Z	Phase 2	[5]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[6]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[7]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[8]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[9]
Tedalinab	DM58J7E	Pain	MG30-MG3Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4	Company report (Gwpharm)
5	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
6	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
7	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
8	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
9	Clinical pipeline report, company report or official report of Roche
10	Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010